What's happening in Neurology® Genetics
Citation Manager Formats
Make Comment
See Comments

Papers appearing in the October 2019 issue
A family with spinocerebellar ataxia and retinitis pigmentosa attributed to an ELOVL4 mutation
Objective
To identify the genetic cause of autosomal dominant spinocerebellar ataxia and retinitis pigmentosa in a large extended pedigree.
Methods
Clinical studies were done at 4 referral centers. Ten individuals in the same extended family participated in at least a portion of the study. Records were obtained from an 11th, deceased, individual. Neurologic and dermatological examinations were performed. Ophthalmologic evaluation including funduscopic examination and in some cases ocular coherence tomography were used to identify the presence of retinal disease. Whole exome sequencing (WES), in conjunction with Sanger sequencing and segregation analysis, was used to identify potential genetic mutation.
Results
Affected individuals reported slowly progressive cerebellar ataxia with age at onset between 38 and 57. Imaging demonstrated cerebellar atrophy (3/3). WES identified a novel heterozygous mutation in the elongation of very long chain fatty acids 4 (ELOVL4) gene (c.512T > C, p.Ile171Thr) that segregated with ataxia in 7 members tested. Four of 8 members who underwent ophthalmologic evaluation were found to have retinitis pigmentosa. No skin findings were identified or reported. Ocular movement abnormalities and pyramidal tract signs were also present with incomplete penetrance.
Conclusions
We report a family with both spinocerebellar ataxia and retinal dystrophy associated with an ELOVL4 mutation. In addition, to supporting prior reports that ELOVL4 mutations can cause spinocerebellar ataxia, our findings further broaden the spectrum of clinical presentations associated with spinocerebellar ataxia 34.
Homozygous pathogenic variant in BRAT1 associated with nonprogressive cerebellar ataxia
Objective
To investigate the pathogenicity of a novel homozygous BRAT1 variant in 2 siblings with nonprogressive cerebellar ataxia (NPCA) through functional studies on primary and immortalized patient cell lines.
Methods
BRAT1 protein levels and ataxia-telangiectasia mutated (ATM) kinase activity in patient-derived and control cell lines were assessed by Western blotting. The impact of the novel BRAT1 variants on mitochondrial function was also assessed, by comparing patient and control cell lines for rates of oxygen consumption and for phosphorylation (S293) of the E1⍺ subunit of pyruvate dehydrogenase (PDH).
Results
Two male siblings with NPCA, mild intellectual disability, and isolated cerebellar atrophy were found to be homozygous for a c.185T>A (p.Val62Glu) variant in BRAT1 by WES. Western blotting revealed markedly decreased BRAT1 protein levels in lymphocytes and/or fibroblast cells from both affected siblings compared to control cell lines. There were no differences between the patient and control cells in ATM kinase activation, following ionizing radiation. Mitochondrial studies were initially suggestive of a defect in regulation of PDH activity, but there was no evidence of increased phosphorylation of the E1⍺ subunit of the PDH complex. Measurement of oxygen consumption rates similarly failed to identify differences between patient and control cells.
Conclusions
Biallelic pathogenic variants in BRAT1 can be associated with NPCA, a phenotype considerably milder than previously reported. Surprisingly, despite the molecular role currently proposed for BRAT1 in ATM regulation, this disorder is unlikely to result from defective ATM kinase or mitochondrial dysfunction.
Most-Read Articles
As of October 3, 2019
KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients
J.J. Millichap, K.L. Park, T. Tsuchida, et al. 2016;2:e96. doi.org/10.1212/NXG.0000000000000096
Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk
B. Rhead, M. Bäärnhielm, M. Gianfrancesco, et al. 2016;2:e97. doi.org/10.1212/NXG.0000000000000097
The Clinical Outcome Study for dysferlinopathy: An international multicenter study
E. Harris, C.L. Bladen, A. Mayhew, et al. 2016;2:e89. doi.org/10.1212/NXG.0000000000000089
CHCHD10 variant p.(Gly66Val) causes axonal Charcot-Marie-Tooth disease
M. Auranen, E. Ylikallio, M. Shcherbii, et al. 2015;1:e1. doi.org/10.1212/NXG.0000000000000003
Phenotypic and molecular analyses of primary lateral sclerosis
H. Mitsumoto, P.L. Nagy, C. Gennings, et al. 2015;1:e3. doi.org/10.1212/01.NXG.0000464294.88607.dd
- © 2019 American Academy of Neurology
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.